Change over period: —
NSE · NECLIFE
NECTAR LIFE
-55.1% from the 52-week high · +7.4% above the low
Nectar Lifesciences Ltd. is a holding company, which engages in the manufacture and distribution of pharmaceutical products. The company is headquartered in Chandigarh, Chandigarh. The company went IPO on 2005-07-19. The firm has developed fully integrated sustainable production systems to manufacture cephalosporin intermediates, active pharmaceuticals ingredients (APIs) and finished dosage formulations (FDF or Formulations) to meet the diverse requirements of its customer base in India and approximately 75 countries worldwide. The firm operates only in the business segment of Pharmaceuticals Products. The Company’s products include Cefixime, Cefuroxime Axetil, Ceftriaxone Sodium, and Menthol and its derivatives. The Company’s subsidiaries include Nectar Lifesciences USA, LLC; Nectar Lifesciences UK Limited, United Kingdom and Neclife PT, Unipessoal LDA, Portugal.
The short version. Return on equity was -50.3% in Mar 2026. Promoter holding was 51.84% in Sep 2026, up 7.31 points over 8 quarters.
1 · The price
How has the stock traded?
NECTAR LIFE trades 55.1% below its 52-week high and 7.4% above its 52-week low.
2 · The business
Is it growing?
28286.1 pts higher than a year earlier.
Revenue compounded at -81.9% over the same 3 years.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 8 | 1 | 5 | 281 | 431 | 455 |
| Net profit | 3 | -15 | -68 | 14 | -176 | -63 | -130 | 8 |
| Net margin % | 24763.6 | -106191.0 | -896.1 | 2159.5 | -3522.5 | -22.5 | -30.2 | 1.7 |
| EPS (₹) | 0.14 | -0.79 | -3.5 | 0.64 | -7.85 | -2.82 | -5.8 | 0.35 |
Annual
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 9 | 1673 | 1686 | 1525 | 1669 | 1544 | 2367 | 2783 |
| Net profit | -293 | -114 | 5 | -24 | 25 | -73 | 32 | 48 |
| Net margin % | -3152.5 | -6.8 | 0.3 | -1.6 | 1.5 | -4.7 | 1.3 | 1.7 |
| EPS (₹) | -15.08 | -5.07 | 0.22 | -1.08 | 1.12 | -3.27 | 1.42 | 2.12 |
3 · The quality
How well does it turn capital into profit?
Return on equity was -50.3% in Mar 2026; debt to equity is 0.00.
Profitability · 4 years
Returns and margins
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | |
|---|---|---|---|---|
| Return on equity % | -50.3 | -11.9 | 0.5 | -2.3 |
| Return on capital % | -8.7 | -8.5 | 8.6 | 2.9 |
| EBITDA margin % | -553.4 | -1.5 | 9.8 | 6.1 |
| Net margin % | -3152.4 | -6.8 | 0.3 | -1.5 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | -81.9% | -64.0% |
| Profit CAGR | 129.7% | 31.9% |
4 · The owners
Who holds it, and are they adding?
Up 7.31 pts over 8 quarters.
Down 0.23 pts over 8 quarters.
Up 3.9 pts over 8 quarters.
+0 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 44.53 | 44.53 | 44.53 | 44.91 | 44.91 | 51.84 | 51.84 | 51.84 | +7.31 |
| FII | 0.73 | 1.65 | 0.81 | 0.62 | 0.52 | 0.6 | 0.5 | 0.5 | -0.23 |
| DII | 0 | 0.16 | 0.19 | 0.09 | 5.82 | 4.01 | 3.74 | 3.9 | +3.9 |
| Public | 54.72 | 53.65 | 54.44 | 54.37 | 48.73 | 43.52 | 43.89 | 43.74 | -10.98 |
Mutual fund holdings · Oct 2026
0 schemes hold this stock
0 the month before.
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for NECTAR LIFE are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Pharmaceuticals & Biotechnology stocks
Quick answers
Common questions about NECTAR LIFE
What is the NECTAR LIFE share price?
NECTAR LIFE (NECLIFE) last closed at ₹9.98, down 0.1% on the day. Its 52-week range is ₹9.30 to ₹22.25.
What is the market cap of NECTAR LIFE?
NECTAR LIFE has a market capitalisation of about ₹194 crore. Its price-to-earnings ratio is 0.9.
How are NECTAR LIFE's latest results?
Return on equity was -50.3% in Mar 2026. Promoter holding was 51.84% in Sep 2026, up 7.31 points over 8 quarters.
Who owns NECTAR LIFE?
As of Sep 2026, shareholding was: Promoter 51.84%, FII 0.5%, DII 3.9%, Public 43.74%.
How many mutual funds hold NECTAR LIFE?
0 mutual fund schemes held NECTAR LIFE in October 2026. That compares with 0 the month before.
Corporate actions
Recent dividends, bonuses and splits
- 11 Sep 2020 · Final Dividend - Rs. 0.05
- 19 Sep 2019 · Final Dividend - Rs. 0.05
- 19 Sep 2018 · Final Dividend - Rs. 0.05
- 20 Sep 2017 · Final Dividend - Rs. 0.05
- 22 Sep 2016 · Final Dividend - Rs. 0.1
- 22 Sep 2015 · Final Dividend - Rs. 0.1
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.